Abs 380: Geriatric assessment incorporated into a real transplant workflow. Took only 5-6 minutes of provider time! And see thread for what that 5-6 min tells you... #ASH19#gerihemegrants.nih.gov/grants/guide/p…
Survival: lower OS with impairment on Timed Up and Go
Duration of hospitalization longer with frailty on Clinical Frailty Scale, IADL limitations, abnormal grip strength, impaired Timed Up and Go, and poorer self-reported health. #ASH19#geriheme
• • •
Missing some Tweet in this thread? You can try to
force a refresh
I am not burned out. I love what I do. I love my patients and I love my research. I am not quitting my calling. I am being brave enough to be CEO of my own life. @RUBraveEnough 2/
Why? “Alignment between your career & your core values produces satisfaction, a sense of happiness & fulfillment. A misalignment can cause can everything from minor problems to major disruptions.” 3a/
Abs 694: Dr Puiz presents GEM-Claridex trial of Rd vs Clarithromycin-RD. Got to witness Sweet moment at end when her mentor @mvmateos flashed her the “Great job, my protege!” smile we all need to see ❤️
GEM-Clarieex provides another cautionary tale about a myeloma regimen that is more effective but more toxic in older patients #geriheme....
Very inclusive with pts into their 90s. Significantly greater CR, >=VGPR rates. We should celebrate 🎉 right? But....
Blown away by rising star @mwschoen's masterful storytelling of how he is trying to understand and eradicate racial disparities in myeloma treatment and outcomes...
file:///var/folders/mw/0w9f93f97wscrp764dmz0k900000gp/T/com.apple.iChat/Messages/Transfers/IMG_6462.jpeg #ASH19
@mwschoen Dr. Schoen walks us through a hypothesis that renal impairment and racial differences in estimating renal function may impact treatment and outcome: 1) Pts with renal dies less likely to receive lenalidomide.
@mwschoen 2) Black veterans have higher creatinine but better GFR... if clinician only looks at creatinine, may err in understanding pts renal function.
Abs 268: @HiraSMian presents data on >5700 pts with MM from Canadian registry with some good/some sobering news for #geriheme pts: 1. ASCT use rising 2. 60% of older pts get a novel drug 3. 20% 1-yr mortality 4. 30% of older patients received NO MYELOMA TREATMENT #ASH19
Even with universal coverage, older pts, lower SES or more comorbidities less likely to be treated for myeloma #mmsm#geriheme#ASH19
High 1-yr mortality for older pts with myeloma who don’t receive treatment. We saw similar rate untreated in SEER- Medicare database. #gerihemencbi.nlm.nih.gov/m/pubmed/29429…
Abstract 67: all new patients with blood cancer age >=75 screened for frailty; participants randomized to receive geriatric consultation. Outcomes: feasibility, 1-yr OS, acute care utilization, goals of care discussion. ash.confex.com/ash/2019/webpr…
86% participated in RCT, but some patients worried that geriatric consultation would make them ineligible for treatment. Just heard this same observation from another #geriheme MD on the opposite side of the country just last night! @ROlinMD
@ROlinMD Outcomes: OS not improved (Abel says geriatrics is not magic!) but geriatric consultation did increase documented goals-of-care conversations. #geriheme#gerionc#ASH19